8BT Stock Overview
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BriaCell Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.10 |
| 52 Week High | CA$6.35 |
| 52 Week Low | CA$1.85 |
| Beta | 1.75 |
| 1 Month Change | -5.41% |
| 3 Month Change | -41.01% |
| 1 Year Change | n/a |
| 3 Year Change | -26.57% |
| 5 Year Change | 4,900.00% |
| Change since IPO | 723.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8BT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.0% | -1.2% | 1.7% |
| 1Y | n/a | -23.0% | 2.3% |
Price Volatility
| 8BT volatility | |
|---|---|
| 8BT Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Volatility Over Time: 8BT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 16 | Bill Williams | briacell.com |
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
BriaCell Therapeutics Corp. Fundamentals Summary
| 8BT fundamental statistics | |
|---|---|
| Market cap | €34.33m |
| Earnings (TTM) | -€11.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs 8BT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8BT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.61m |
| Earnings | -US$12.61m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.79 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 8BT perform over the long term?
See historical performance and comparison